Alpha DNA Investment Management’s O-I Glass OI Stock Holding History

Alpha DNA Investment Management’s Portfolio OI Stock Details OI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-48,129	Closed	-$1.09M	–	206
2023 Q1	$1.09M	Sell	48,129 -14,963	-24%	-$314K	0.32%	78
2022 Q4	$1.05M	Buy	+63,092	New	+$1.02M	0.37%	112

Other funds holding OI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Canada Life Winnipeg, Manitoba, Canada $55.8B AUM 26.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpha DNA Investment Management's OI Position: Q2 2023 in Review

Alpha DNA Investment Management sold out of O-I Glass (OI) in Q2 2023, closing a stake of 48,129 shares — an estimated $1.09M sold.

Alpha DNA Investment Management first reported a position in OI in Q4 2022 and held it in 2 quarters. The position peaked at $1.09M in Q1 2023. 298 funds tracked by Wall St. Rank hold OI as of Q2 2023.

Alpha DNA Investment Management reported no remaining O-I Glass position as of Q2 2023 after selling out during the quarter.
Alpha DNA Investment Management sold 48,129 O-I Glass shares in Q2 2023, an estimated $1.09M.
Alpha DNA Investment Management first reported a position in O-I Glass in Q4 2022 and held it in 2 quarters.
Alpha DNA Investment Management's O-I Glass position peaked at $1.09M in Q1 2023.
298 funds tracked by Wall St. Rank held O-I Glass as of Q2 2023.

Based on Alpha DNA Investment Management's 13F filing for Q2 2023, filed 31 Jul 2023.